Preliminary results of the alternating administration of natural interferon‐α and recombinant interferon‐γ for metastatic renal cell carcinoma

Abstract

Objective To evaluate the eBcacy and toxicity of the median and maximum time to remission in the responders were 2 and 7 months, respectively. The alternating administration of natural (n) interferon (IFN)-a and recombinant (r) IFN-c for metastatic RCC.survival time of the responders was significantly longer than that of those not responding (stable and progressPatients and methods The study comprised 24 patients (median age 60 years, range 42-77), 20 of whom ive disease, P=0.0202). Toxicities were mostly limited to WHO grades 1 and 2, with grade 3 leucopenia and were evaluable for response and all 24 evaluable for toxicity. Initially, nIFN-a was administered subcutanegrade 4 hepatic dysfunction in only one patient each. These toxicities were transient and there were no ously on days 1 and 3, and rIFN-c on day 2, for 1-2 weeks in the evening or at night, both at doses treatment-related deaths. Conclusion The alternating administration of nIFN-a and of 3 MU. If this regimen was tolerated, nIFN-a and rIFN-c were administered at the same doses on days rIFN-c is an eCective treatment for metastatic RCC. This treatment is particularly suitable for patients who 1, 3 and 5, and on days 2 and 4, respectively. Results There were three complete remissions and two have undergone nephrectomy and have lung metastases. partial remissions, giving a total response rate of 25%. All responders (complete plus partial remission) had Keywords Renal cell carcinoma, immunotherapy, IFN-a, IFN-c combination therapy undergone nephrectomy. Multiple lung metastases completely disappeared from four responders. The [5,6]. These two IFNs have diCerent receptors on the cell

Successful Treatment With Novel Triple Drug Combination Consisting of Interferon-γ, Interferon Alfacon-1, and Ribavirin in a Nonresponder HCV Patient to Pegylated Interferon Therapy

“…No significant, unexpected adverse events were noted; there was an acceptable safety and tolerability profile in this group of patients. Beside hepatitis B, the experience with combination therapy with interferon-α and interferon-γ is in oncologic conditions, where significant, unexpected toxicities have not been seen (10)(11)(12)(13)(14).…”

Interferon‐γ Therapy: Evaluation of Routes of Administration and Delivery Systems

“…IFN‐γ has applications in the treatment of a number of immunological, viral, and neoplastic diseases. These include systemic sclerosis,16 asthma,17 atopic dermatitis,18 myelogenous leukemia,19 hairy cell leukemia,20 cutaneous leishmaniasis,21 lepromatous leprosy,22 sclerodoma,23,24 granuloma annulare,25 melanoma,26 and metastatic renal cell carcinoma 4,27,28. IFN‐γ currently is approved by the Food and Drug Administration (FDA) for reducing the frequency and severity of serious infections associated with chronic granulomatous disease and for delaying time to disease progression in patients with severe, malignant osteopetrosis.…”